Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a strong sell rating in a research note published on Sunday morning.

A number of other equities analysts have also recently issued reports on the stock. Raymond James Financial assumed coverage on shares of Milestone Pharmaceuticals in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price objective on the stock. Wells Fargo & Company cut their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Zacks Research lowered shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Milestone Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $7.25.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.51 on Friday. The firm’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $1.93. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06. The stock has a market capitalization of $187.37 million, a price-to-earnings ratio of -2.21 and a beta of 1.04. The company has a current ratio of 9.18, a quick ratio of 9.09 and a debt-to-equity ratio of 1.61.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $30.12 million. As a group, equities analysts predict that Milestone Pharmaceuticals will post -0.96 earnings per share for the current year.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 36,500 shares of Milestone Pharmaceuticals stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. The trade was a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIST. Strategic Family Wealth Counselors L.L.C. bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $25,000. Eaton Financial Holdings Company LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $26,000. Welch & Forbes LLC bought a new stake in Milestone Pharmaceuticals during the first quarter worth about $30,000. Bank of America Corp DE boosted its stake in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares in the last quarter. Finally, Cetera Investment Advisers bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $42,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.